Tucson, United States
Regulonix Holding, Inc., founded in 2017, is an early-stage biotechnology company headquartered in the United States. The company is committed to tackling the global health epidemic of chronic pain through the development of non-opioid drugs, as articulated in their slogan: "Non-opioid drugs for chronic pain to attack a global health epidemic."
Regulonix stands out by focusing on indirectly targeting the sodium channel NaV1.7, a critical and genetically validated pain target. By concentrating on the signaling pathways controlling this channel’s activity, the company has developed compounds that appear in animal models to be non-addictive, with higher efficacy than morphine. This innovative approach positions Regulonix in the rapidly expanding global pain management therapeutics market, estimated to reach $83B by 2024.
Financially, Regulonix last secured a $2.00M Seed Round investment on 10 July 2018, led by investors Desert Angels and UAventure Capital. The company's forward-thinking strategies and promising results indicate its potential as a strong contender in revolutionizing pain management.
